GLP-1 and Anxiety: What We Know, What’s Rumor, and What to Do If You Feel Worse

Is Anxiety Listed as a Side Effect? What the Prescribing Labels Actually Say

Before we get into studies and speculation, let’s start with what’s in the official FDA-approved prescribing information — the documents your doctor is supposed to follow. This matters because most articles online blur the line between “what’s in the label” and “what someone posted on Reddit.”

We pulled data directly from the current prescribing information for each major GLP-1 medication. Here’s what we found:

*†Note on Saxenda: In the STEP-8 head-to-head trial, liraglutide had 15.0% “Psychiatric disorders” system organ class events (driven largely by insomnia) vs. 5.6% for semaglutide — but this is a broad category, not an anxiety-specific rate.

Sources: Wegovy prescribing information (novo-pi.com/wegovy.pdf); Zepbound prescribing information (pi.lilly.com/us/zepbound-uspi.pdf); Saxenda prescribing information revised 02/2026 (novo-pi.com/saxenda.pdf); FDA Drug Safety Communication, January 13, 2026.

The mistake many articles make

Here’s something important that most posts get wrong: the 4% anxiety figure for Wegovy comes from the pediatric (ages 12–17) adverse reaction table, not adults. And in several prescribing labels, “anxiety” appears as a symptom of low blood sugar, not as a standalone side effect of the medication itself.

That’s a meaningful distinction. If your blood sugar drops because you’re eating significantly less on a GLP-1, you might feel anxious, shaky, irritable, and sweaty. That’s hypoglycemia mimicking anxiety — not the drug directly causing psychiatric symptoms.

We’re not saying medication-related anxiety doesn’t happen. We’re saying you deserve accuracy about what the labels actually say before reading someone else’s interpretation.

Feeling Anxious on a GLP-1 Right Now? Start Here

If you’re reading this mid-anxiety episode, you don’t need a research review. You need a quick answer: Is this dangerous, and what do I do right now?

Quick sort: Is this anxiety — or something else that feels like anxiety?

This is the part most pages skip, and it matters a lot. Many GLP-1 “anxiety” symptoms have a physical explanation that’s easier to fix than you’d think. Ask yourself these questions:

What to do in the next 24 hours

These are safe, general actions — not medical advice, but common sense while you wait to talk to your provider:

• Hydrate aggressively. Water plus electrolytes. GLP-1 side effects (nausea, vomiting, reduced appetite) can dehydrate you faster than you realize.
• Eat something. Even if you’re not hungry. A small meal with protein and complex carbs can stabilize blood sugar.
• Cut stimulants temporarily. Reduce caffeine by half for 48 hours and see what happens.
• Track the timing. Write down: when you injected, when anxiety started, what you ate, how you slept, your caffeine intake. Patterns matter — and this data is exactly what your prescriber needs.
• Don’t stop your medication abruptly. Stopping suddenly can cause rebound effects, blood sugar spikes, and rapid weight regain. Always work with your prescriber first.

When to call your prescriber (don’t wait for your next appointment)

• Anxiety is persistent (more than a few days) or worsening week over week
• You’re having panic attacks you’ve never experienced before
• You can’t sleep more than 4 hours per night
• You feel emotionally numb, “flat,” or disconnected
• Symptoms cluster around dose escalation and don’t resolve within a week
• You’re on psychiatric medication and suspect it’s not working as well

What Did the FDA Actually Find? (The 2026 Update Most Pages Are Missing)

In January 2026, the FDA completed the most comprehensive review of GLP-1 medications and mental health to date. This matters because it directly contradicts a lot of what you’ll read online.

What they did

The FDA conducted a meta-analysis of 91 placebo-controlled clinical trials involving 107,910 patients — 60,338 on a GLP-1 medication and 47,572 on placebo. This covered every FDA-approved GLP-1 receptor agonist.

They also analyzed healthcare claims data from the FDA Sentinel System — a national electronic database covering nearly 2.25 million patients — comparing GLP-1 users to users of SGLT2 inhibitors (another popular diabetes drug class).

What they found

What they didn’t say

The FDA did not say “GLP-1s cannot affect mood in any individual.” What they said is that at a population level, across the largest dataset we have, there’s no signal. They still recommend monitoring for mood changes — “no increased risk on average” is not the same as “zero risk for every person.”

This distinction matters. If you’re one of the people who does feel different on a GLP-1, the FDA review doesn’t invalidate your experience. It means your symptoms may have an explanation other than a direct psychiatric effect of the drug — and that’s actually useful information, because those other explanations (blood sugar, dehydration, sleep, medication interactions) are often fixable.

Source: FDA Drug Safety Communication, January 13, 2026. “FDA Requests Removal of Suicidal Behavior and Ideation Warning from Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medications.”

Why Do Some Studies Show the Opposite? (And What That Means for You)

If the FDA says no increased risk, why do other studies show higher anxiety rates? The answer isn’t that someone is lying — it’s that different study types answer different questions.

Understanding the evidence hierarchy

Why the Scientific Reports study (108% increased risk) sounds scarier than it is

This study gets cited everywhere, usually without context. Researchers looked at 162,253 propensity-score-matched patients using the TriNetX database — half on GLP-1s, half not. They found GLP-1 users had higher rates of anxiety, depression, and suicidal behavior diagnoses.

But here’s what they couldn’t control for:

• People who start GLP-1s see doctors more often, get screened more, and are more likely to receive a psychiatric diagnosis — not necessarily develop one.
• They didn’t account for concurrent medications. If someone started an SSRI at the same time, that wouldn’t be captured.
• They couldn’t separate the drug from the weight loss. Rapid weight loss itself — from any cause, including surgery — is independently associated with mood changes and anxiety.
• Obesity itself carries higher psychiatric risk. People prescribed GLP-1s already have elevated baseline rates of anxiety and depression.

Why real-world studies sometimes show the opposite — lower anxiety

A 2024 Epic Research analysis of electronic health records found that most GLP-1 medications were actually correlated with a lower likelihood of anxiety and depression diagnoses after starting treatment. Semaglutide specifically showed this pattern in non-diabetic patients.

In a Taiwanese nationwide cohort of adults with diabetes, GLP-1 RA use — especially longer than 180 days — was associated with a lower risk of anxiety diagnoses (aHR 0.41), and dulaglutide was associated with lower risk of both anxiety and depression.

Sources: Epic Research, 2024; Tsai WH et al., Frontiers in Pharmacology, 2022 (diabetes cohort); Kornelius et al., Scientific Reports, 2024.

How GLP-1 Medications Actually Affect Your Brain (The Science, in Plain Language)

GLP-1 was originally thought of as a “gut hormone.” It’s not. GLP-1 receptors are found throughout your brain — in the amygdala (your brain’s fear and anxiety center), the hippocampus (memory and stress processing), the nucleus accumbens (reward and pleasure), and the dorsal raphe nucleus (the main hub for serotonin production).

This is why a medication designed to reduce appetite can also affect mood, motivation, pleasure, and anxiety. It’s not a bug in the system — it’s the biology.

The paradox: GLP-1 can be both anxiety-increasing AND anxiety-reducing

This is the single most important scientific finding that almost nobody is communicating clearly, and it explains a lot of the confusion.

A landmark 2016 study published in Psychoneuroendocrinology tested GLP-1 and its long-acting analog Exendin-4 in rodents across multiple anxiety tests. Here’s what they found:

• Acute (single-dose) GLP-1 receptor activation increased anxiety-like behavior. This was consistent across three different anxiety tests.
• Chronic (ongoing) GLP-1 receptor activation did not increase anxiety — and actually reduced depression-like behavior.
• The antidepressant effect was not simply from weight loss. Control rats that were pair-fed (given the same reduced food intake) did not show the same mood improvement.
• Acute GLP-1 altered serotonin signaling in the amygdala — literally changing the chemistry of the brain’s fear center.

Source: Anderberg RH, Richard JE, Hansson C, et al. “GLP-1 is both anxiogenic and antidepressant; divergent effects of acute and chronic GLP-1 on emotionality.” Psychoneuroendocrinology. 2016;65:54-66.

Three layers: Why some people feel anxious on GLP-1s

Not every case of GLP-1-related anxiety has the same explanation. We’ve organized the most common causes into three layers — and the fix is different for each one.

Is This Normal or a Red Flag? How to Tell the Difference

This is the section that doesn’t exist anywhere else, and it’s the one we think matters most. Not every person experiencing anxiety on a GLP-1 is in the same situation.

Scenario A: Early-treatment adjustment (most common)

Scenario B: Side-effect-driven anxiety

Scenario C: Medication interaction (under-recognized, potentially serious)

Scenario D: Red flags — contact your provider now

Scenario E: Pre-existing anxiety resurfacing

Do GLP-1s Interact With Anxiety Meds or ADHD Meds?

This is one of the most under-discussed topics in the GLP-1 conversation, and based on what we see in prescribing labels and pharmacovigilance data, it shouldn’t be.

The key mechanism: delayed gastric emptying

GLP-1 receptor agonists slow down how quickly food (and medications) move through your stomach. This is part of how they work — it increases satiety and reduces appetite. But it also means oral medications may be absorbed more slowly or unpredictably. The Zepbound prescribing information explicitly notes this: tirzepatide delays gastric emptying and may impact absorption of concomitant oral medications.

What this means by medication type

What to ask your prescriber

Who Is Most Likely to Experience Anxiety on a GLP-1?

Not everyone has the same risk profile. Based on the available evidence, certain groups should be monitored more closely.

People with pre-existing mental health conditions

If you have a history of panic disorder, generalized anxiety disorder, OCD, PTSD, postpartum anxiety, or depression, you deserve extra monitoring — not because GLP-1s are proven to worsen these conditions, but because:

1. You were excluded from the clinical trials that established GLP-1 safety data. We simply have less controlled evidence for your situation.
2. You may be on medications whose absorption could be affected.
3. Rapid weight loss and body change carry psychological weight that intersects with pre-existing conditions.
4. You may be more sensitive to the acute neurobiological effects of GLP-1 receptor activation.

This does not mean GLP-1s are off-limits. It means you need a prescriber who screens for mental health, monitors regularly, and has a plan if symptoms emerge.

People on certain medications

Anyone taking oral psychiatric medications — especially SSRIs, SNRIs, benzodiazepines, or stimulants — has an additional risk factor due to potential absorption changes. People combining GLP-1s with insulin or sulfonylureas face higher hypoglycemia risk, which mimics anxiety.

People with significant behavioral changes

If you’ve dramatically reduced calories, stopped eating comfort foods entirely, quit or reduced alcohol, changed your exercise routine substantially, and/or are sleeping poorly — all at the same time as starting a GLP-1 — you’ve changed multiple variables simultaneously. Any one of those could drive anxiety. Teasing apart which factor is responsible requires tracking.

Anxiety Data by Specific GLP-1 Medication

Not all GLP-1s are the same molecule, and the data differs. If you’re considering switching medications, this breakdown matters.

Ozempic (Semaglutide 1 mg) and Anxiety

Ozempic is the lower-dose form of semaglutide, approved for type 2 diabetes. It has never carried a suicide-related warning. Anxiety is not listed as an adverse reaction in the adult prescribing information — it appears only as a symptom of low blood sugar. Ozempic and Wegovy contain the same molecule, but Wegovy is used at a higher dose (2.4 mg vs. 1 mg). If you’re sensitive to side effects, dose may matter.

Wegovy (Semaglutide 2.4 mg) and Anxiety

In clinical trials, 4% of adolescent patients (ages 12–17) reported anxiety compared to 2% on placebo. In January 2026, the FDA requested removal of the suicidal ideation warning. In the STEP-8 head-to-head trial, semaglutide had a 5.6% rate of psychiatric events — compared to 15.0% for liraglutide and 10.6% for placebo.

A post-hoc analysis of the STEP trials published in JAMA Internal Medicine found that semaglutide 2.4 mg did not increase depression or suicidal ideation compared to placebo.

Mounjaro and Zepbound (Tirzepatide) and Anxiety

Tirzepatide is a dual GIP/GLP-1 receptor agonist. Anxiety is not listed as an adverse reaction in either prescribing label. The SURMOUNT trials did not prominently flag psychiatric events. If semaglutide-based medications are causing anxiety issues for you, tirzepatide is a reasonable option to discuss with your prescriber — but be aware that the psychiatric data is thinner, not necessarily better.

Saxenda (Liraglutide 3 mg) and Anxiety

The psychiatric data here is the least favorable. In the STEP-8 head-to-head trial, liraglutide had a 15.0% “Psychiatric disorders” system organ class event rate (driven largely by insomnia) — compared to 5.6% for semaglutide and 10.6% for placebo.

GLP-1 and Dopamine: Emotional Blunting, Anhedonia, and “Ozempic Personality”

“Ozempic personality” is the pop-culture term for mood and behavior changes some people report on GLP-1 medications — feeling “flat,” losing interest in things they used to enjoy, emotional numbness, or personality shifts.

What’s known vs. what’s speculation

GLP-1 receptors are present in the nucleus accumbens — the brain’s reward center — and in dopaminergic pathways. GLP-1 medications appear to modulate dopamine signaling, which is why they reduce cravings for food, alcohol, nicotine, and other substances. But dopamine doesn’t just drive cravings. It drives motivation, anticipation, pleasure, and engagement with life. If a medication turns down dopamine signaling broadly, some people may experience reduced pleasure across the board.

What to do if you feel emotionally “flat”

• Don’t dismiss it. This is a real experience reported by enough people to warrant attention.
• Track it. Is it getting worse, stable, or improving? Did it start with a dose change?
• Talk to your prescriber. They may adjust your dose or consider switching medications.
• Consider therapy. If you’ve lost food as a coping mechanism, a therapist who specializes in body image and adjustment can help.
• Don’t stop abruptly. Always work with your medical team before changing medications.

Can GLP-1 Medications Actually Help Anxiety or Depression?

This might sound contradictory after everything above, but it’s an important part of the full picture — and it’s increasingly supported by evidence.

Why some people feel better on GLP-1s

• Reduced “food noise.” The constant mental chatter about food quiets down. For people whose anxiety was partly driven by food-related stress, this feels like genuine relief.
• Improved physical health and self-efficacy. Losing weight, improving blood sugar control, having more energy, sleeping better.
• Reduced systemic inflammation. Obesity is associated with chronic low-grade inflammation, which is increasingly linked to depression and anxiety.
• The chronic biological effect. As the rodent research suggests, chronic GLP-1 receptor activation may have genuine antidepressant properties independent of weight loss.

What the research says (without overclaiming)

In a Taiwanese nationwide cohort (Tsai WH et al., Frontiers in Pharmacology, 2022), GLP-1 RA use — especially longer than 180 days — was associated with a significantly lower risk of anxiety diagnoses (aHR 0.41, 95% CI 0.27–0.61). Dulaglutide specifically was associated with lower risk of both anxiety and depression.

Researchers are now conducting trials of GLP-1 medications for bipolar disorder, substance use disorders, and depression. Roger McIntyre, a prominent psychiatry researcher, wrote in Psychiatric Times (July 2025) that GLP-1 receptor agonists represent “a transformative possibility” for psychiatric medicine.

If You’re Using Compounded Semaglutide or Tirzepatide

As of February 2026, the FDA maintains active warnings about unapproved GLP-1 products. Their concerns include dosing errors, temperature/shipping problems, fraud (counterfeit products), salt forms that haven’t been evaluated for safety, and adverse events that are harder to report or trace.

Why this matters for anxiety specifically

If you’re using a compounded GLP-1 and experiencing anxiety, you have an additional variable: you may not be getting the dose you think you’re getting.

• Overdosing can intensify GI side effects, which create the anxiety cascade (nausea → not eating → low blood sugar → anxiety symptoms).
• Underdosing followed by correct dosing can feel like an abrupt increase, triggering the acute anxiety response.
• Incorrect salt forms may have different pharmacokinetic profiles — meaning they’re absorbed differently.

How to evaluate your compounded product

• Is it from a state-licensed compounding pharmacy (not a “wellness center” or online reseller)?
• Did it arrive temperature-controlled (cold chain maintained)?
• Are dosing instructions clear and specific (not vague)?
• Does the pharmacy have a verifiable physical address and pharmacist-in-charge?
• Red flags: spelling errors on packaging, claims it’s “research use only,” no pharmacy license number, prices dramatically below market rate.

How to Start (or Continue) a GLP-1 If You Have Anxiety: A Step-by-Step Plan

Before your first dose

• Establish a baseline. Rate your anxiety 0–10 for a week before starting. This gives you (and your prescriber) a reference point.
• Tell your prescriber about your mental health history. All of it. Including medications, previous episodes, and current symptoms.
• Set up a tracking system. A simple daily log: anxiety level, sleep quality, food intake, hydration, caffeine, injection date.
• Identify your “check-in” person. A partner, friend, or therapist who can give you honest feedback about behavior changes you might not notice yourself.
• Optimize sleep and hydration before starting. You’ll be better equipped to handle any adjustment symptoms if your baseline is solid.

The first 4 weeks

• Expect GI side effects. Nausea is the most common. Have anti-nausea strategies ready.
• Eat enough. The appetite suppression can be dramatic. Eating too little is the fastest route to the anxiety cascade.
• Watch dose-escalation timing. If anxiety spikes after a dose increase, note the pattern. Your prescriber may slow the titration schedule.
• Don’t add other big changes. This isn’t the week to start intermittent fasting, a new exercise program, and a caffeine detox simultaneously.

Ongoing

• Each dose increase is a new potential trigger window. Treat it like a mini re-start — monitor closely for 1–2 weeks after each escalation.
• If symptoms cluster around dose increases and resolve between them, discuss slower titration with your prescriber. Not everyone needs to be on the highest dose.

What to Tell Your Prescriber (Copy-Paste Scripts)

We know it can be hard to articulate what you’re feeling, especially when you’re anxious. Here are templates you can message or bring to your appointment.

The 60-second message

If you suspect a medication interaction

If you want to discuss switching GLP-1s

What to Do Next

You’ve made it through the most complete breakdown of GLP-1 and anxiety available anywhere. Here’s what matters most:

• If your anxiety is mild and improving: Keep tracking, optimize the basics (hydration, food, sleep, caffeine), and check in with your prescriber at your next appointment. The acute biological response may resolve on its own.
• If your anxiety is persistent or worsening: Don’t wait. Contact your prescriber. Bring your symptom data. Use the scripts above. There are options — dose adjustment, slower titration, switching medications, timing changes for other medications.
• If you’re choosing a GLP-1 provider and mental health matters to you: Not all providers are the same. The best ones screen for mental health at intake, offer regular check-ins, have clear protocols for side effect management, and either provide or refer to mental health support. See our full provider comparison →

You don’t have to choose between weight loss and mental health. With the right provider, the right monitoring, and the right information — which you now have — you can pursue both.

Frequently Asked Questions About GLP-1 and Anxiety

Sources

Every factual claim in this article is cited below. We prioritize randomized controlled trials and FDA communications over observational studies and social media analysis. Where evidence is mixed, we say so.

1. FDA Drug Safety Communication (January 13, 2026). “FDA Requests Removal of Suicidal Behavior and Ideation Warning from Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medications.” fda.gov
2. Wegovy Prescribing Information. Novo Nordisk. Current version. novo-pi.com/wegovy.pdf
3. Zepbound Prescribing Information. Eli Lilly. Current version. pi.lilly.com/us/zepbound-uspi.pdf
4. Saxenda Prescribing Information. Novo Nordisk. Revised 02/2026. novo-pi.com/saxenda.pdf
5. Anderberg RH, Richard JE, Hansson C, et al. “GLP-1 is both anxiogenic and antidepressant; divergent effects of acute and chronic GLP-1 on emotionality.” Psychoneuroendocrinology. 2016;65:54-66.
6. Wadden TA, Brown GK, Egebjerg C, et al. “Psychiatric Safety of Semaglutide for Weight Management.” JAMA Internal Medicine. 2024. jamanetwork.com
7. Kornelius E, et al. “The risk of depression, anxiety, and suicidal behavior in patients with obesity on glucagon-like peptide-1 receptor agonist therapy.” Scientific Reports. 2024. nature.com
8. Schoretsanitis G, Weiler S, Barbui C, Raschi E, Gastaldon C. “Disproportionality Analysis From World Health Organization Data on Semaglutide, Liraglutide, and Suicidality.” JAMA Network Open. 2024;7(8):e2423385. jamanetwork.com
9. Epic Research. “Most GLP-1 Medications Correlated With a Lower Likelihood of Anxiety and Depression Diagnoses.” 2024. epic.com
10. Arillotta D, et al. “GLP-1 Receptor Agonists and Related Mental Health Issues; Insights from a Range of Social Media Platforms.” Brain Sciences. 2023;13(11):1503.
11. Sa M, et al. “Psychiatric effects of GLP-1 receptor agonists: A systematic review.” Diabetes, Obesity and Metabolism. 2026.
12. French nationwide case-time-control study. “Suicide and suicide attempt in users of GLP-1 receptor agonists.” Lancet eClinicalMedicine. 2024.
13. Tsai WH, Sung FC, Chiu LT, et al. “Decreased Risk of Anxiety in Diabetic Patients Receiving Glucagon-like Peptide-1 Receptor Agonist.” Frontiers in Pharmacology. 2022;13:765446. pubmed.ncbi.nlm.nih.gov
14. FDA. “FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.” Updated 2025. fda.gov
15. NPR. “As Ozempic use grows, so do reports of possible mental health side effects.” September 2023.
16. Primary Care Companion CNS Disord. “Efficacy of GLP-1 Agonists in Psychiatric Illnesses: A Scoping Review.” 2025;27(3).
17. McIntyre RS. “Transformation 2.0: The GLP-1 RAs as Psychiatric Medications?” Psychiatric Times. July 2025.
18. Zheng W, et al. “Psychiatric adverse events associated with GLP-1 receptor agonists: A FAERS-based pharmacovigilance analysis.” Frontiers in Pharmacology. 2024. pmc.ncbi.nlm.nih.gov